New hope for rare cancers: first human trial of ANS03 begins

NCT ID NCT06716138

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called ANS03 in adults with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check safety and find the right dose. About 96 participants will receive the drug, and doctors will monitor side effects and any tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

NTRK fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States
Research Site
RECRUITING

Fuzhou, Fujian, China
Research Site
RECRUITING

Guangzhou, Guangdong, China
Research Site
RECRUITING

Shanghai, Shanghai Municipality, China
Research Site
RECRUITING

Chengdu, Sichuan, China